Prognostic factors for stage IV gastric cancer.
作者信息
Baba Hiroyuki, Kuwabara Koki, Ishiguro Toru, Kumamoto Kensuke, Kumagai Yoichi, Ishibashi Keiichiro, Haga Norihiro, Ishida Hideyuki
机构信息
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan.
出版信息
Int Surg. 2013 Apr-Jun;98(2):181-7. doi: 10.9738/INTSURG-D-12-00027.1.
Abstract
摘要
相似文献
1
Prognostic factors for stage IV gastric cancer.IV期胃癌的预后因素。
Int Surg. 2013 Apr-Jun;98(2):181-7. doi: 10.9738/INTSURG-D-12-00027.1.
2
Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.新辅助化疗后胃腺癌五种肿瘤退缩分级系统的比较：一项来自中国国家癌症中心192例病例的回顾性研究
BMC Gastroenterol. 2017 Mar 14;17(1):41. doi: 10.1186/s12876-017-0598-5.
3
PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.PRODIGY 研究：新辅助多西他赛、奥沙利铂和 S-1 联合手术与手术联合辅助 S-1 治疗可切除的晚期胃癌的 III 期研究。
J Clin Oncol. 2021 Sep 10;39(26):2903-2913. doi: 10.1200/JCO.20.02914. Epub 2021 Jun 16.
4
Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.对于接受 D2 胃切除术和 S-1 辅助化疗的 II/III 期胃癌患者，肿瘤宏观大小是独立的预后因素。
Gastric Cancer. 2011 Aug;14(3):274-8. doi: 10.1007/s10120-011-0038-0. Epub 2011 Apr 2.
5
Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification.根据最新的 TNM 分类对根治性手术后 III 期胃癌的预后分析。
Clin Transl Oncol. 2019 Feb;21(2):232-238. doi: 10.1007/s12094-018-1913-5. Epub 2018 Jul 2.
6
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.通过代谢和靶酶活性预测胃癌对氟嘧啶类药物的敏感性
Gastric Cancer. 2003;6 Suppl 1:71-81. doi: 10.1007/s10120-003-0221-z.
7
Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery.胃癌手术后口服抗癌药物辅助化疗 2 年的预后效果。
Surg Today. 2012 Aug;42(8):734-40. doi: 10.1007/s00595-012-0129-5. Epub 2012 Jan 27.
8
Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.淋巴结比值是选择适当辅助化疗方案治疗可切除 D2 胃腺癌的重要临床决定因素。
J Cancer Res Clin Oncol. 2019 Aug;145(8):2157-2166. doi: 10.1007/s00432-019-02963-7. Epub 2019 Jul 4.
9
10
Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer.S-1联合顺铂治疗晚期胃癌的临床疗效
Gastric Cancer. 2003;6 Suppl 1:45-9. doi: 10.1007/s10120-003-0222-y.
引用本文的文献
1
Targeting kinesin family member 21B by miR-132-3p represses cell proliferation, migration and invasion in gastric cancer.miR-132-3p 通过靶向驱动蛋白家族成员 21B 抑制胃癌细胞的增殖、迁移和侵袭。
Bioengineered. 2022 Apr;13(4):9006-9018. doi: 10.1080/21655979.2022.2054755.
2
Deep learning-based virtual cytokeratin staining of gastric carcinomas to measure tumor-stroma ratio.基于深度学习的胃癌虚拟细胞角蛋白染色测量肿瘤间质比。
Sci Rep. 2021 Sep 28;11(1):19255. doi: 10.1038/s41598-021-98857-1.
3
The Diagnostic and Prognostic Value of miR-200c in Gastric Cancer: A Meta-Analysis.miR-200c 在胃癌中的诊断和预后价值：一项荟萃分析。
Dis Markers. 2019 Apr 4;2019:8949618. doi: 10.1155/2019/8949618. eCollection 2019.
4
Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India.印度北卡纳塔克邦胃腺癌中HER2NEU表达的免疫组织化学评估
Asian Pac J Cancer Prev. 2018 May 26;19(5):1381-1385. doi: 10.22034/APJCP.2018.19.5.1381.
5
Correlations of MMP-2 and TIMP-2 gene polymorphisms with the risk and prognosis of gastric cancer.基质金属蛋白酶-2（MMP-2）和金属蛋白酶组织抑制因子-2（TIMP-2）基因多态性与胃癌风险及预后的相关性
Int J Clin Exp Med. 2015 Nov 15;8(11):20391-401. eCollection 2015.
6
Prognostic role of gastrectomy in patients with gastric cancer with positive peritoneal cytology.胃切除术在腹膜细胞学检查阳性的胃癌患者中的预后作用。
Int Surg. 2014 Nov-Dec;99(6):830-4. doi: 10.9738/INTSURG-D-14-00119.1.
本文引用的文献
1
Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry.2002 年在日本治疗的胃癌：JGCA 全国注册处 2009 年度报告。
Gastric Cancer. 2013 Jan;16(1):1-27. doi: 10.1007/s10120-012-0163-4. Epub 2012 Jun 23.
2
Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer.S-1 单药治疗与 S-1 联合顺铂治疗老年晚期胃癌患者的安全性和疗效比较。
Int J Clin Oncol. 2013 Feb;18(1):10-6. doi: 10.1007/s10147-011-0335-y. Epub 2011 Oct 22.
3
New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points.日本胃癌新分类及治疗指南：修订理念与主要修订要点
Gastric Cancer. 2011 Jun;14(2):97-100. doi: 10.1007/s10120-011-0040-6.
4
Japanese gastric cancer treatment guidelines 2010 (ver. 3).《日本胃癌治疗指南2010（第3版）》
Gastric Cancer. 2011 Jun;14(2):113-23. doi: 10.1007/s10120-011-0042-4.
5
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.2008 年全球癌症负担估计值：GLOBOCAN 2008。
Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
6
Treatment for gastric carcinoma in the oldest old patients.高龄胃癌患者的治疗。
Gastric Cancer. 2011 Jun;14(2):139-43. doi: 10.1007/s10120-011-0022-8. Epub 2011 Feb 19.
7
Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer.S-1 单药治疗老年晚期胃癌患者的安全性和有效性。
Gastric Cancer. 2010 Nov;13(4):245-50. doi: 10.1007/s10120-010-0566-z. Epub 2010 Dec 3.
8
Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954.新辅助化疗对比单纯手术治疗局部进展期胃和胃食管交界腺癌：欧洲癌症研究与治疗组织 40954 随机临床试验。
J Clin Oncol. 2010 Dec 10;28(35):5210-8. doi: 10.1200/JCO.2009.26.6114. Epub 2010 Nov 8.
9
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.S-1联合顺铂与单用S-1作为晚期胃癌一线治疗的疗效比较（SPIRITS试验）：一项III期试验
Lancet Oncol. 2008 Mar;9(3):215-21. doi: 10.1016/S1470-2045(08)70035-4. Epub 2008 Feb 20.
10
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.使用口服氟嘧啶S-1对胃癌进行辅助化疗。
N Engl J Med. 2007 Nov 1;357(18):1810-20. doi: 10.1056/NEJMoa072252.
Zotero 插件